Coronavirus disease (COVID-19) has generated interest in the assessment of systemic immune status, but existing knowledge about mucosal immunity is clearly insufficient to understand the full pathogenetic mechanisms of the disease. The aim of this study was to evaluate the long-term effects of novel coronavirus infection on mucosal immunity in the postinfection period among health care workers (HCWs). A total of 180 health care workers with and without a history of COVID-19 who ranged in age from 18 to 65 years were enrolled in this one-stage, cross-sectional study. The study subjects completed the 36-Item Short Form (36) Health Survey (SF-36) and the Fatigue Assessment Scale. Secretory immunoglobulin A (sIgA) and total immunoglobulin G (IgG) levels were quantified in saliva samples, induced sputum samples, and nasopharyngeal and oropharyngeal scrapings by an enzyme-linked immunosorbent assay. Specific anti-SARS-CoV-2 IgG antibodies were quantified in serum samples by chemiluminescence immunoassay. Analysis of the questionnaire data showed that all HCWs with a history of COVID-19 reported health problems that limited their daily activities and negative changes in their emotional health three months after the disease, regardless of its severity. The following shifts were detected in the adaptive arm of the immune response in different mucosal compartments. Among subjects who had severe or moderate-to-severe COVID-19, salivary sIgA levels were significantly higher than those in the control group (p < 0.05 and p < 0.005, respectively). Compared to the subjects in the control group, all subjects with prior COVID-19 had significantly higher levels of total IgG in induced sputum. In the group of patients who had had severe infection, total IgG in saliva was also higher (p < 0.05). A direct statistically significant correlation was also detected between the levels of total IgG in all studied samples and the levels of specific IgG antibodies against SARS-CoV-2 in the serum. A significant correlation was observed between total IgG levels and the parameters of physical and social activities, mental health, and fatigue levels. Our study demonstrated long-term changes in the humoral mucosal immune response, which were most pronounced in health care workers with a history of severe or moderate-to-severe COVID-19, and an association of these changes with certain clinical signs of post-COVID-19 syndrome.
A great deal of evidence has accumulated suggesting an important role of mucosal immunity not only in preventing COVID-19 but also in the pathogenesis of this infection. The aim of the study was to evaluate the levels of secretory immunoglobulin A (sIgA) in different compartments of the upper respiratory tract in COVID-19 patients in relation to the severity of the disease and treatment with a bacteria-based immunomodulating agent (Immunovac VP4). The titers of sIgA were determined by ELISA in nasal epithelial swabs, pharyngeal swabs, and salivary gland secretions at baseline and on days 14 and 30 of treatment. The levels of nasal, pharyngeal and salivary sIgA were significantly lower in more severe patients (subgroup A) than in less severe patients (subgroup B), p < 0.01. In subgroup A, the patients who received Immunovac VP4 had higher pharyngeal sIgA levels in convalescent period than those who did not receive the therapy p < 0.05. In subgroup B patients, an increase in immunoglobulin levels was observed from baseline to day 14 of treatment whether they received the add-on therapy or not, p < 0.01. On day 30 of treatment, the sIgA levels in the standard treatment group, however, decreased, while the patients receiving the immunomodulating agent maintained high sIgA levels, p < 0.05. Oxygen saturation significantly increased by day 14 in both groups, p < 0.001. However, it was higher in the Immunovac VP4 group than in the standard treatment group, p < 0.01. Thus, addition of a bacterial lysate-based immunomodulating agent to the treatment regimen for moderate-to-severe COVID-19 induces the production of pharyngeal and salivary sIgA. SIgA production is inversely correlated to CRP levels and percentage of lung involvement on CT scan and is directly correlated to SpO2 levels.
22 September 2023 in Russian Journal of Immunology
Currently, the role of local respiratory tract immunoglobulins in COVID-19 and rearrangement of mucosal immune response in the post-COVID period have not been sufficiently studied. Our aim was to evaluate long-term effects of novel coronavirus infection on the mucosal immunity in healthcare workers over the post-infection period. A total of 180 healthcare workers, ranging in age from 18 to 65 years, were enrolled in a one-stage, cross-sectional study. The subjects with a history of COVID-19 were divided into three groups, depending on the severity of their disease. The control group consisted of 44 healthcare workers who had no history of novel coronavirus infection. Secretory immunoglobulin A (sIgA) and total immunoglobulin G (IgG) levels were quantified in saliva samples, induced sputum samples, naso- and oropharyngeal scrapings by ELISA technique. Specific anti-SARS-CoV-2 IgG antibodies were quantified in the serum by chemiluminescence immunoassay. Numerous shifts in adaptive immune response were detected for different mucosal compartments, i.e., in subjects who suffered from severe or moderate-to-severe COVID-19, salivary sIgA levels were significantly higher than those in the control group (p 0.05 and p 0.005, respectively). An inverse correlation was demonstrated between the levels of total sIgA in all mucosal sites, and the number of days from the onset of disease to the start of study (r = 0.278, р 0.05). When compared to the control subjects, all the patients with prior COVID-19 had significantly higher levels of total IgG in the induced sputum samples. Total IgG in saliva was also higher in the group of patients who had severe infection (p 0.05). By contrast, IgG levels in nasopharyngeal samples were decreased in severe and moderately severe groups compared to the control group, thus, probably, indicating an immunodeficiency state in these cases. A direct significant correlation was also detected between the levels of total IgG in all studied samples and the levels of specific IgG antibodies against SARS-CoV-2 in the serum. Long-term changes in the humoral mucosal immune response were most pronounced in the healthcare workers with a history of severe or moderate-to-severe COVID-19.
Phagocytic component of mucosal immunity in individuals infected with SARS-CoV-2 virus and COVID-19 convalescents is an understudied area. An important role in understanding haemophagocytic lymphohistiocytosis syndrome was played by the Russian researcher I.I. Mechnikov. Aims and objectives: To evaluate phagocytic component of respiratory mucosal immunity and a general level of phagocytic activity in blood of HCPs with COVID-19 history and ones without it. Materials and methods: Сross-sectional study included 182 HCPs (161 F/21 M, aged 47.3±12.7) after 125.1±71.1 days from the disease onset. Participants were divided into 4 groups: 1- severe, 2- moderate, 3- mild disease in history, 4- no disease. The examination included saliva, induced sputum, naso- and oropharyngeal mucosa scrapings, and venous blood samples. Phagocytic activity of blood leukocytes was determined by a cytofluometry flow in reaction with FITC-labeled staphylococci. Phagocytic activation index was determined by nitroblue tetrazolium reduction test. Results: The level of phagocytic index of granulocytes in the 2nd group (95,53±4,06) differed from the 3rd group (97,02±3,02) and from the 4th (97,44±1,89), p<0,05. Reduced reserve of bactericidal activity was observed in persons of 1rd and 2nd groups (1.99±0.75 and 2.27±0.88 respectively) compare to the 4th group (2.71±1.37; p<0.05). Values of phagocytic index of salivary granulocytes were lower in the group with severe disease (27,74±18,71) in comparison with HCPs without COVID-19 (48,82±27,42; p<0,05). Conclusion: The revealed changes indicate dysregulation of the innate immune response in the post COVID-19 period at the level of the mucosa as well as in blood.
Background: Influenza vaccine is a tool for preventing infection and reducing exacerbations in patients with asthma and chronic obstructive pulmonary disease (COPD). Purpose of this study is to investigate dynamics of CRP and serum cytokines (IL-2, IL-6, IL-10, IL-17) in patients with asthma and COPD, as well as to perform a correlation analysis with the clinical parameters of the disease manifestation. Methods: The study included 34 patients with asthma, 20 patients with COPD vaccinated against influenza during a period of remission from 2 to 4 weeks, both groups being under a basic maintenance therapy, and 26 healthy individuals vaccinated with the trivalent polymer-subunit vaccine Grippol® Plus, containing 5 µg of influenza virus strains and 500 µg of azoximer bromide. Results: Observing patients with asthma and COPD, during a year after the vaccination, has revealed a significant reduction in exacerbations frequency (p < 0.05) and duration (p < 0.05) of the bronchial obstructive syndrome (BF). Before the vaccination the IL-6 level in patients with asthma had a direct moderate correlation with duration of exacerbations of the underlying disease (p < 0.05), along with the number of systemic corticosteroids courses during exacerbations (p < 0.05). In 12 months after the vaccination, while assessing cytokine profile of all study groups, a significant reduction in the level of IL-6 was observed, compared to the baseline values (p< 0.05). Conclusion: Conducted analysis of immunological, clinical, and functional parameters of patients with asthma and COPD has proven for influenza vaccine to be effective in BF patients.
Introduction: Most COVID-19 studies investigate changes in systemic immunity mechanisms, rather than in mucosal immunity - one that plays an important role defending against the respiratory pathogens. Aims and objectives: assessment of the respiratory tract mucosal immunity in healthcare professionals (HCPs) with COVID-19 history and ones without it. Materials and Methods: The cross-sectional study included 73 HCPs (65 females/8 males, mean age 47.1±12.3 years). There were four study groups: 1) severe disease (n=11), 2) moderate disease (n=21), 3) mild and asymptomatic disease (n=20), 4) no disease (n=21). The examination included saliva, induced sputum, nasopharyngeal, and oropharyngeal mucosa scrapings. Enzyme-linked immunosorbent assay determined secretory IgA (sIgA) (µg/L) and IgG (µg/mL) levels. The data are presented as Me (Q1; Q3). Results: Salivary IgA levels were higher (p<0.05) in patients of the 1st and 2nd groups (73.10 (64.15; 107.75) and 122.17 (67.53; 152.20) respectively) than in patients of the 3rd and 4th groups (56.73 (41.93; 76.31) and 2.09 (47.81; 73.06) respectively). Salivary IgG levels were higher in convalescent HCPs with severe (0.042 (0.015; 0.043)) and moderate (0.031 (0.011; 0.045)) disease in history compare to HCPs without COVID-19 (0.017 (0.04; 0.028), р<0.05). IgG levels in induced sputum samples were also higher in the 1st (0.025 (0.013; 0.036)) and the 2nd (0.018 (0.014; 0.040) groups compare to persons of the 4th (0.006 (0.000; 0.015)), p<0.05. Conclusions: The revealed changes indicate the residual inflammatory response of mucosal immunity in COVID-19 convalescents. The formation of a specific local immune response against the COVID-19 is also possible.